# Statin and Bone Health

Study · id `cardio:ct-nct05613400` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05613400](<https://clinicaltrials.gov/study/NCT05613400>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05613400

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

## Technical summary

Registry record NCT05613400. Randomized; double masking; primary purpose health services research. Start 2022-04-13 (actual); primary completion 2024-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose health services research
- Phase: Phase 4
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT05613400, source copy `cardio:ctgov-nct05613400-2022-11-28`, retrieved 2026-10-26)
- Started: 2022-04-13 (actual) (ClinicalTrials.gov record NCT05613400, source copy `cardio:ctgov-nct05613400-2022-11-28`, retrieved 2026-10-26)
- Primary completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT05613400, source copy `cardio:ctgov-nct05613400-2022-11-28`, retrieved 2026-10-26)
- Completion: 2025-06-30 (anticipated) (ClinicalTrials.gov record NCT05613400, source copy `cardio:ctgov-nct05613400-2022-11-28`, retrieved 2026-10-26)
- Countries: Hong Kong SAR China (ClinicalTrials.gov record NCT05613400, source copy `cardio:ctgov-nct05613400-2022-11-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05613400-2022-11-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Statin and Bone Health
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Simvastatin 10mg
- Intervention (Drug): Ezetimibe 10mg
- Lead sponsor: The University of Hong Kong
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: The University of Hong Kong (`cardio:org-the-university-of-hong-kong`)

## Provenance

Content hash: 3a793f8c29234b5bc0644d3685a39fadf60436416459ef1eff4d29c31c48d29d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
